CROS


Also found in: Acronyms, Idioms, Wikipedia.

CROS

(kros),
Abbreviation and acronym for contralateral routing of signal.
References in periodicals archive ?
Though the global CRO market is facing various challenges, it is expected to grow a healthy growth rate during the forecast period owing to increase in M&A activities among the companies, increase in R&D investment by various companies, establishment of large number of clinical trial outsourcing organizations in emerging markets and increase in private equity investment particularly for R&D activities.
Ernst & Young has observed a marked shift in reporting lines: Many CROs now report directly to the CEO and the board of directors.
CROs now believe they may actually affect the pace, extent and seriousness to which their own organizations implement regulations such as the Own Risk and Solvency Assessment, according to EY's survey.
This enables CROs provides their specialized services on a for fee for service basis based on the afore-mentioned relationships.
A chief risk officer (CRO) is a relatively new addition to the corporate hierarchy.
Services Domestic WuXi Shanghai 2000 Preclinical, PharmaTech clinical, manufacturing Domestic ShangPharma Shanghai 2002 Preclinical, manufacturing Domestic Tigermed Hangzhou 2000 Clinical, regulatory Domestic HD Shanghai 2002 Preclinical Biosciences Foreign PPD Beijing 2003 Preclinical, clinical Foreign Quintiles Beijing 1997 Clinical, commercialization Foreign Covance Beijing 1998 Preclinical, clinical JV Rundo Shanghai 2004 Clinical (Sino-Japan) JV KendleWits Beijing 1997 Clinical (Sino-US) JV Pharmaron Beijing 2003 Preclinical, (Sino-US) manufacturing JV VenturePharm Beijing 1999 Preclinical, (Sino-US) clinical, manufacturing Table 1: Examples of CROs divided by domestic, foreign, and JV CHINESE CRO SERVICES
In part, the gravy train and less stringent regulations raised all boats; but with all pharma companies being squeezed today, CROs need to address the enrollment problem or they're going to imperil future success, as well as jeopardize lives with costly delays in trials for otherwise promising medicines.
Therapeutic areas of focus for CROs. Oncology, Cardiovascular diseases, Dermatology, Neurology, and Respiratory diseases are the top five focus areas for the surveyed CRO firms.
The high potential for future change in responsibilities and demands for the CRO position is exemplified by change within the careers of current CROs.
The Report of Global Preclinical CRO Market by Market Research Future Covers the Information like Preclinical CRO Market Growth, Top 10 Players, Upcoming Trends, chapter-wise Description followed by various user perceptions.
Menlo Park, CA, June 11, 2019 --(PR.com)-- Life Science Strategy Group (LSSG), a leading strategic consulting firm to the CRO industry, is pleased to announce the availability of its 2019 syndicated report on Real-World Evidence - "A Market at an Inflection Point and its Impact on the CRO Industry." This benchmark study provides a detailed look into the pharmaceutical industry's utilization of real-world evidence (RWE), the changing RWD/RWE landscape within biopharmaceutical companies and its implications on CRO business models and strategies.